Tumor Mutational Burden (TMB) is an emerging, independent predictive biomarker of immunotherapies

Tumor Mutational
Burden (TMB)


Tumor Mutational Burden (TMB) is an emerging, independent predictive biomarker of immunotherapies in multiple tumor types, including lung cancer.

ORDER NOW

What is Tumor Mutational Burden (TMB)?

Tumor Mutational Burden (TMB) is an emerging, independent predictive biomarker of immunotherapies in multiple tumor types, including lung cancer.

Refers to the total number of somatic mutations that exist within a tumor’s genome.

A subset of these mutations may result in expressed proteins, termed neo-antigens, that are not recognized by the host’s immune system as self, and therefore have the potential to be immunogenic, leading to an anti-tumor immune-mediated response.

TMB Clinical Utility

Tumors with a high mutation burden may have a higher rate of neo-antigens which, in principle, would be expected to be more immunogenic than tumors with comparatively low mutation burden.

Technical Info

The test is performed using the Oncomine™ Tumor Mutation Load Assay (409 genes). It is a robust targeted NGS assay, that provides accurate quantitation of somatic mutations to assess tumor mutation burden, in formalin-fixed, paraffin-embedded (FFPE) tissues.

Change cookies consent Revoke cookies consent